Key result
Proactive screening for neuromuscular disorders in patients with cardiomyopathies is recommended to identify individuals at risk of cardiac arrhythmias and emboli requiring prophylactic treatments.
Cardiologists should proactively screen for neuromuscular disorders in patients with cardiomyopathies to identify those at risk for arrhythmias and heart failure who may need specific prophylactic treatments.
May support neuromuscular screening consideration in cardiomyopathies; leaves open prospective validation of arrhythmia and emboli prevention.
The link between heart and skeletal muscle disorders is based on similar molecular, anatomical and clinical features, which are shared by the 'primary' cardiomyopathies and 'primary' neuromuscular disorders. There are, however, some peculiarities that are typical of cardiac and skeletal muscle disorders. Skeletal muscle weakness presenting at any age may indicate a primary neuromuscular disorder (associated with creatine kinase elevation as in dystrophinopathies), a mitochondrial disease (particularly if encephalopathy, ocular myopathy, retinitis, neurosensorineural deafness, lactic acidosis are present), a storage disorder (progressive exercise intolerance, cognitive impairment and retinitis pigmentosa, as in Danon disease), or metabolic disorders (hypoglycaemia, metabolic acidosis, hyperammonaemia or other specific biochemical abnormalities). In such patients, skeletal muscle weakness usually precedes the cardiomyopathy and dominates the clinical picture. Nevertheless, skeletal involvement may be subtle, and the first clinical manifestation of a neuromuscular disorder may be the occurrence of heart failure, conduction disorders or ventricular arrhythmias due to cardiomyopathy. ECG and echocardiogram, and eventually, a more detailed cardiovascular evaluation may be required to identify early cardiac involvement. Paediatric and adult cardiologists should be proactive in screening for neuromuscular and related disorders to enable diagnosis in probands and evaluation of families with a focus on the identification of those at risk of cardiac arrhythmia and emboli who may require specific prophylactic treatments, for example, pacemaker, implantable cardioverter-defibrillator and anticoagulation.
No takes yet. Share an insight, caveat, or question.
Limongelli et al. (2013) conducted a review in Cardiomyopathies and neuromuscular disorders. Proactive screening for neuromuscular disorders in patients with cardiomyopathies is recommended to identify individuals at risk of cardiac arrhythmias and emboli requiring prophylactic treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: